These findings, together with our observations of the inhibitory effect of NSAIDs on A
Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists Use in Elderly People With Obesity-A Meta-Analysis
HbA1c staying above target despite metformin Overweight or obesity, especially the abdominal fat pattern common in Indians Existing cardiovascular disease or high cardiac risk a topic we cover in depth in Part 8: GLP-1, Heart and Kidney Benefits Chronic kidney disease, where GLP-1 drugs have shown protective signals [7] A need to avoid hypoglycemia or further weight gain, which older drugs like sulfonylureas often cause DPP-4 inhibitors such as teneligliptin, sitagliptin, vildagliptin, and linagliptin are widely prescribed in India and lower blood glucose with a low risk of hypoglycemia
Food and Drug Administration (FDA) approved Rybelsus in September 2019 as the first oral GLP-1 receptor agonist for adults with type 2 diabetes
Differences in study design, statistical methods, and population characteristics may explain these inconsistencies
In patients with normal kidney function, it was strongly and significantly associated with the risk of venous thromboembolism (Brodin 2012)
